Shots:

• Boehringer Ingelheim to acquire all shares of NBE-Therapeutics for ~$1.434B which include contingent clinical and regulatory milestones. The transaction is expected to be closed in Q1’21
• The acquisition will add NBE-Therapeutics’ ROR1-directed ADCs including NBE-002 which is currently in P-I studies for TNBC and other solid tumors
• NBE-Therapeutics’ iADC platform will add exceptional tumor-targeting capabilities to Boehringer Ingelheim’s oncology portfolio. The deal comes one month after Merck’s $2.8B acquisition of VelosBio for its anti-ROR1 ADC

 ­ Ref: Boehringer Ingelheim | Image: Business Wire